Imago’s main prize is bomedemstat, a drug candidate that’s in phase 2 trials for multiple blood disorders including essential thrombocythemia, myelofibrosis and polycythemia vera.
The transaction, which will merge Merck’s acquisition subsidiary and Imago, is expected to be finalized in the first quarter of 2023.
